Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud impacting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by misleading information regarding Merck's expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts for Gardasil's growth in China were based on claims of successful consumer activation and education efforts [2] - On February 4, 2025, Merck announced it would not meet the projected $11 billion in sales, ceasing shipments to China to reduce inventory due to lower-than-expected demand [2] Group 2: Stock Impact - Following the announcement on February 4, 2025, Merck's stock price dropped from $99.79 to $90.74, a decline of over 9% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]